BReast cancer Ex vivo Anthracycline Sensitivity Test (BREAST) study;Using ex vivo drug sensitivity tests to optimize breast cancer therapy in the future
Completed
- Conditions
- breast carcinoma10006291
- Registration Number
- NL-OMON43367
- Lead Sponsor
- Interne Oncologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
• Age >18 years
• WHO performance status 0 or 1
• Planned treatment with anthracycline-based NAC (either 3 courses of FEC or 4 courses of AC)
• Written informed consent
Exclusion Criteria
• Planned treatment with TAC (taxanes concomitant with anthracyclines) courses
• Current therapeutical use of anti-coagulant (coumarin derivates, warfarin, heparin or low molecular weight heparin [LMWH]) whereby a short interruption of drug use is not allowed. LMWH use in a prophylactic dose is allowed
• Any psychological condition potentially hampering compliance with the study protocol
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method